Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.

Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

Peptide News from Biotech and Pharma, Raw News September 26, 2017

... for hypoparathyroidism currently in a phase 1 trial, and TransCon CNP, a long-acting prodrug of C-type Natriuretic Peptide for achondroplasia.